Trials / Conditions / Relapsed/Refractory Mantle Cell Lymphoma
Relapsed/Refractory Mantle Cell Lymphoma
6 registered clinical trials studyying Relapsed/Refractory Mantle Cell Lymphoma.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Active Not Recruiting | Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refr NCT06253663 | Kite, A Gilead Company | Phase 2 |
| Completed | Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Co NCT04880434 | Kite, A Gilead Company | Phase 2 |
| Completed | A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies NCT03886831 | Prelude Therapeutics | Phase 1 |
| Completed | Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Co NCT02601313 | Kite, A Gilead Company | Phase 2 |
| Completed | A Trial of Ibrutinib, Lenalidomide and Rituximab for Patients With Relapsed/Refractory Mantle Cell Lymphoma NCT02460276 | Lund University Hospital | Phase 2 |
| Completed | Lenalidomide With or Without Idelalisib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma NCT01838434 | Alliance for Clinical Trials in Oncology | Phase 1 |